spinout | GenomeWeb

spinout

The UCSC spinout plans to launch a handheld nanopore sensor this year and will partner with diagnostic and other companies to develop assays.

The Bridget Ogilvie Building will house sequencing facilities, and the Biodata Innovation Centre will host genomic startups.

ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.

Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.

The molecular diagnostics developer will use the money to continue expanding its commercial presence in the cancer diagnostics market.

OncoCyte has spun off as a publicly traded company from BioTime and has begun trading on the NYSE MKT under the symbol OCX.

OmniSeq's goal is to make cancer genomic testing available to institutions, including comprehensive cancer centers, oncology practices, and community oncology groups.

NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market Wednesday that its board of directors has approved the separation of Keysight Technologies, the new name for its electronic measurement subsidiary, from the firm and has named a successor to current CEO Bill Sullivan.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €64.5 million ($84 million) in a round of private financing.

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its long-term rating on Agilent Technologies' debt at 'BBB+' and revised its outlook to stable from positive, following Agilent's announcement earlier in the day that it would

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.